新一代肿瘤免疫治疗不良反应及其防治原则

doi:10.3760/cma.j.issn.1673-422X.2017.06.015

摘要/Abstract

摘要： 近年来肿瘤免疫治疗因其在晚期肿瘤患者中的显著疗效而备受瞩目和推崇，但其常导致免疫相关不良反应。了解免疫检查点抑制剂Ipilimumab、Nivolumab和Pembrolizumab等药物的免疫相关不良反应的发生率、可能发生机制及其不良反应的评估标准及治疗原则，对恶性肿瘤的治疗具有重要意义。

关键词: 免疫疗法, 药物毒性

Abstract: In recent years, tumor immunotherapy has attracted more attention because of its remarkable curative effect in patients with advanced cancer, but often accompanied by immune related adverse events. Understanding the immune related adverse reaction rate, possible mechanism and adverse reaction evaluation criteria and treatment principle of the immune checkpoint inhibitors such as Ipilimumab, Nivolumab and Pembrolizumab, has important significance for the treatment of malignant tumor.

Key words: Immunotherapy, Drug toxicity

刘中正，谢晓冬. 新一代肿瘤免疫治疗不良反应及其防治原则[J]. 国际肿瘤学杂志, 2017, 44(6): 460-.

Liu Zhongzheng, Xie Xiaodong. Adverse reactions of the new generation of tumor immunotherapy and its management strategy[J]. Journal of International Oncology, 2017, 44(6): 460-.

参考文献

［1］ CouzinFrankel J. Breakthrough of the year 2013. Cancer immunotherapy［J］. Science, 2013, 342(6165): 1432-1433. DOI: 10.1126/science.342.6165.1432. ［2］张淑娟, 常建华. 肺癌的免疫治疗［J］. 国际肿瘤学杂志, 2015, 42(10): 776-779. DOI: 10.3760/cma.j.issn.1673422X.2015.10.016. ［3］ Ledford H. Melanoma drug wins US approval［J］. Nature, 2011, 471(7340): 561. DOI: 10.1038/471561a. ［4］ Poole RM. Pembrolizumab: first global approval［J］. Drugs, 2014, 74(16): 1973-1981. DOI: 10.1007/s4026501403145. ［5］ Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic nonsmall cell lung cancer with progression on or after platinumbased chemotherapy［J］. Oncologist, 2016, 21(5): 634-642. DOI: 10.1634/theoncologist.20150507. ［6］ Raedler LA. Opdivo (Nivolumab): second PD1 inhibitor receives FDA approval for unresectable or metastatic melanoma［J］. Am Health Drug Benefits, 2015, 8(Spec Feature): 180-183. ［7］ Markham A. Atezolizumab: first global approval［J］. Drugs, 2016, 76(12): 1227-1232. DOI: 10.1007/s4026501606188. ［8］ Markham A. Elotuzumab: first global approval［J］. Drugs, 2016, 76(3): 397-403. DOI: 10.1007/s4026501605400. ［9］ Weber J, Thompson JA, Hamid O, et al. A randomized, doubleblind, placebocontrolled, phase Ⅱ study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage Ⅲ or Ⅳ melanoma［J］. Clin Cancer Res, 2009, 15(17): 5591-5598. DOI: 10.1158/10780432.CCR091024. ［10］ Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］. N Engl J Med, 2011, 364(26): 2517-2526. DOI: 10.1056/NEJMoa1104621. ［11］ Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in stage ⅢB/Ⅳ nonsmallcell lung cancer: results from a randomized, doubleblind, multicenter phase Ⅱ study［J］. J Clin Oncol, 2012, 30(17): 2046-2054. DOI: 10.1200/JCO.2011.38.4032. ［12］ Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castrationresistant prostate cancer that had progressed after docetaxel chemotherapy (CA184043): a multicentre, randomised, doubleblind, phase 3 trial［J］. Lancet Oncol, 2014, 15(7): 700-712. DOI: 10.1016/S14702045(14)701895. ［13］ Lebbé C, Weber JS, Maio M, et al. Survival followup and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase Ⅱ studies［J］. Ann Oncol, 2014, 25(11): 2277-2284. DOI: 10.1093/annonc/mdu441. ［14］ Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigatorchoice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE002): a randomised, controlled, phase 2 trial［J］. Lancet Oncol, 2015, 16(8): 908-918. DOI: 10.1016/S14702045(15)000832. ［15］ Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PDL1positive, advanced nonsmallcell lung cancer (KEYNOTE010): a randomised controlled trial［J］. Lancet, 2016, 387(10027): 1540-1550. DOI: 10.1016/S01406736(15)012817. ［16］ Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma［J］. N Engl J Med, 2015, 372(26): 2521-2532. DOI: 10.1056/NEJMoa1503093. ［17］ Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma［J］. JAMA, 2016, 315(15): 1600-1609. DOI: 10.1001/jama.2016.4059. ［18］ Weber JS, D′angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after antiCTLA4 treatment (CheckMate 037): a randomised, controlled, openlabel, phase 3 trial［J］. Lancet Oncol, 2015, 16(4): 375-384. DOI: 10.1016/S14702045(15)700768. ［19］ Rizvi NA, Mazières J,Planchard D, et al. Activity and safety of nivolumab, an antiPD1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmallcell lung cancer (CheckMate 063): a phase 2, singlearm trial［J］. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S14702045(15)700549. ［20］ Motzer RJ, Rini BI, Mcdermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase Ⅱ trial［J］. J Clin Oncol, 2015, 33(13): 1430-1437. DOI: 10.1200/JCO.2014.59.0703. ［21］ Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamouscell nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(2): 123-135. DOI: 10.1056/NEJMoa1504627. ［22］ Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events［J］. J Am Acad Dermatol, 2014, 71(1): 161-169. DOI: 10.1016/j.jaad.2014.02.035. ［23］ Klein O, Ebert LM, Nicholaou T, et al. MelanAspecific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with antiCTLA4［J］. Clin Cancer Res, 2009, 15(7): 2507-2513. DOI: 10.1158/10780432.CCR082424. ［24］ Cheng R, Cooper A, Kench J, et al. Ipilimumabinduced toxicities and the gastroenterologist［J］. J Gastroenterol Hepatol, 2015, 30(4): 657-666. DOI: 10.1111/jgh.12888. ［25］ Ryder M, Callahan M, Postow MA, et al. Endocrinerelated adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution［J］. Endocr Relat Cancer, 2014, 21(2): 371-381. DOI: 10.1530/ERC130499. ［26］ Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologicfindings［J］. Invest New Drugs, 2013, 31(4): 1071-1077. DOI: 10.1007/s1063701399396. ［27］ Marrone KA, Ying W, Naidoo J. Immunerelated adverse events from immune checkpoint inhibitors［J］. Clin Pharmacol Ther, 2016, 100(3): 242-251. DOI: 10.1002/cpt.394. ［28］ Choi JN. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab［J］. Semin Cutan Med Surg, 2014, 33(1): 40-48. ［29］ Nancey S, Boschetti G, Cotte E, et al. Blockade of cytotoxic Tlymphocyte antigen4 by ipilimumab is associated with a profound longlasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumabinduced severe enterocolitis?［J］. Inflamm Bowel Dis, 2012, 18(8): E1598-E1600. DOI: 10.1002/ibd.21927. ［30］ Tarhini A. Immunemediated adverse events associated with ipilimumab ctla4 blockade therapy: the underlying mechanisms and clinical management［J］. Scientifica(Cairo), 2013, 2013: 857519. DOI: 10.1155/2013/857519.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[4]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[5]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[8]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[9]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[11]	过慈良, 江春平, 吴俊华. 肠道菌群与肿瘤免疫治疗[J]. 国际肿瘤学杂志, 2023, 50(7): 432-436.
[12]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	顾安琴, 龙金华, 金风. 鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.
[15]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.